DK3528817T3 - Fremgangsmåder til behandling af leverforstyrrelser eller lipidforstyrrelser med en thr-beta-agonist - Google Patents
Fremgangsmåder til behandling af leverforstyrrelser eller lipidforstyrrelser med en thr-beta-agonist Download PDFInfo
- Publication number
- DK3528817T3 DK3528817T3 DK17804979.7T DK17804979T DK3528817T3 DK 3528817 T3 DK3528817 T3 DK 3528817T3 DK 17804979 T DK17804979 T DK 17804979T DK 3528817 T3 DK3528817 T3 DK 3528817T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- thr
- methods
- treating liver
- beta agonist
- Prior art date
Links
- 229940123876 Thyroid hormone receptor beta agonist Drugs 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409833P | 2016-10-18 | 2016-10-18 | |
| US201762516594P | 2017-06-07 | 2017-06-07 | |
| PCT/US2017/057203 WO2018075650A1 (en) | 2016-10-18 | 2017-10-18 | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3528817T3 true DK3528817T3 (da) | 2022-08-08 |
Family
ID=60480362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17804979.7T DK3528817T3 (da) | 2016-10-18 | 2017-10-18 | Fremgangsmåder til behandling af leverforstyrrelser eller lipidforstyrrelser med en thr-beta-agonist |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11090308B2 (https=) |
| EP (2) | EP3528817B1 (https=) |
| JP (3) | JP2019533019A (https=) |
| KR (2) | KR20230156159A (https=) |
| CN (1) | CN110167557A (https=) |
| AU (1) | AU2017346871B2 (https=) |
| CA (1) | CA3040888A1 (https=) |
| DK (1) | DK3528817T3 (https=) |
| ES (1) | ES2924257T3 (https=) |
| IL (2) | IL302336B2 (https=) |
| MX (1) | MX394463B (https=) |
| WO (1) | WO2018075650A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| SI4122464T1 (sl) | 2017-03-28 | 2024-07-31 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| CN110627773B (zh) * | 2018-06-22 | 2021-03-19 | 海创药业股份有限公司 | 氘代mgl-3196化合物及其用途 |
| AR115666A1 (es) * | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
| CA3111025C (en) * | 2018-09-06 | 2023-10-31 | Galmed Research And Development Ltd | Combination therapy for the treatment of liver disease |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN111320609A (zh) * | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| PT3911647T (pt) * | 2019-01-15 | 2024-03-04 | Gilead Sciences Inc | Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| CN113474335B (zh) * | 2019-02-21 | 2024-12-03 | 南京瑞捷医药科技有限公司 | 化合物及其作为甲状腺激素受体激动剂的用途 |
| KR20220017917A (ko) | 2019-05-08 | 2022-02-14 | 알리고스 테라퓨틱스 인코포레이티드 | Thr-베타의 조절제 및 이의 사용 방법 |
| AU2020336272A1 (en) * | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) * | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| WO2021104288A1 (zh) * | 2019-11-26 | 2021-06-03 | 昆药集团股份有限公司 | 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用 |
| CN111562321B (zh) * | 2020-04-16 | 2022-10-28 | 广东省结核病控制中心 | 用于检测活动性肺结核的粪便代谢物及其检测系统 |
| WO2022052822A1 (zh) * | 2020-09-10 | 2022-03-17 | 苏州科睿思制药有限公司 | Resmetirom的晶型及其制备方法和用途 |
| EP4204419A1 (en) | 2020-10-19 | 2023-07-05 | Teva Pharmaceuticals International GmbH | Solid state forms of resmetirom |
| KR20230142523A (ko) * | 2021-02-01 | 2023-10-11 | 마드리갈 파마슈티칼스, 인크. | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 |
| US20250000836A1 (en) * | 2021-07-21 | 2025-01-02 | Cyta Therapeutics, Inc. | Particle delivery of thyroid hormone receptor agonists and antagonists |
| PE20241327A1 (es) * | 2021-11-11 | 2024-06-26 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-beta |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2024263714A1 (en) * | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| WO2025083699A2 (en) | 2023-10-16 | 2025-04-24 | Cipla Limited | Resmetirom polymorphs and process thereof |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025245216A1 (en) * | 2024-05-22 | 2025-11-27 | Terns Pharmaceuticals, Inc. | Treatment of liver disorders with a thr-beta agonist |
| WO2026074443A1 (en) | 2024-10-01 | 2026-04-09 | Assia Chemical Industries Ltd. | Solid state forms of resmetirom |
| CN121648128A (zh) * | 2026-02-03 | 2026-03-13 | 华中科技大学同济医学院附属同济医院 | 特拉唑嗪或其药学上可接受的盐在制备用于预防和/或治疗肝纤维化的药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5615272A (en) | 1979-07-17 | 1981-02-14 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| CN100469769C (zh) | 2003-03-24 | 2009-03-18 | 弗·哈夫曼-拉罗切有限公司 | 作为逆转录酶抑制剂的苄基-哒嗪酮 |
| ITRM20030363A1 (it) | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| US20080152700A1 (en) | 2004-06-01 | 2008-06-26 | Reza Sheikhnejad | Methods and compositions for the inhibition of gene expression |
| US7807647B2 (en) | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
| DK1919878T3 (da) | 2005-07-21 | 2010-10-25 | Hoffmann La Roche | Pyridazinonderivater som thyroidhormonreceptoragonister |
| HRP20100611T1 (hr) | 2007-06-06 | 2010-12-31 | Torrent Pharmaceuticals Ltd | Novi spojevi |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| US8858502B2 (en) | 2012-10-10 | 2014-10-14 | Alcon Research, Ltd. | Systems and methods for external pressure sensing |
| CN106132969A (zh) * | 2014-02-14 | 2016-11-16 | 森普拉制药公司 | 用于治疗糖尿病和肝病的组合物和方法 |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| AR115666A1 (es) | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
-
2017
- 2017-10-18 WO PCT/US2017/057203 patent/WO2018075650A1/en not_active Ceased
- 2017-10-18 JP JP2019542355A patent/JP2019533019A/ja active Pending
- 2017-10-18 EP EP17804979.7A patent/EP3528817B1/en active Active
- 2017-10-18 IL IL302336A patent/IL302336B2/en unknown
- 2017-10-18 MX MX2019004492A patent/MX394463B/es unknown
- 2017-10-18 US US16/343,065 patent/US11090308B2/en active Active
- 2017-10-18 EP EP22175048.2A patent/EP4112056B1/en active Active
- 2017-10-18 IL IL266054A patent/IL266054B2/en unknown
- 2017-10-18 KR KR1020237037485A patent/KR20230156159A/ko active Pending
- 2017-10-18 CA CA3040888A patent/CA3040888A1/en active Pending
- 2017-10-18 AU AU2017346871A patent/AU2017346871B2/en active Active
- 2017-10-18 CN CN201780078133.2A patent/CN110167557A/zh active Pending
- 2017-10-18 KR KR1020197014495A patent/KR20190109387A/ko not_active Ceased
- 2017-10-18 ES ES17804979T patent/ES2924257T3/es active Active
- 2017-10-18 DK DK17804979.7T patent/DK3528817T3/da active
-
2021
- 2021-07-07 US US17/369,197 patent/US11806353B2/en active Active
-
2023
- 2023-09-21 US US18/371,229 patent/US20240156826A1/en not_active Abandoned
- 2023-09-22 JP JP2023157999A patent/JP2024001055A/ja active Pending
-
2025
- 2025-05-12 JP JP2025079296A patent/JP2025122012A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL302336A (en) | 2023-06-01 |
| MX394463B (es) | 2025-03-19 |
| JP2025122012A (ja) | 2025-08-20 |
| AU2017346871B2 (en) | 2023-08-03 |
| CA3040888A1 (en) | 2018-04-26 |
| JP2024001055A (ja) | 2024-01-09 |
| IL266054A (en) | 2019-06-30 |
| EP4112056A1 (en) | 2023-01-04 |
| AU2017346871A1 (en) | 2019-05-02 |
| EP3528817A1 (en) | 2019-08-28 |
| IL266054B2 (en) | 2023-10-01 |
| MX2019004492A (es) | 2019-11-18 |
| US20210330675A1 (en) | 2021-10-28 |
| KR20230156159A (ko) | 2023-11-13 |
| CN110167557A (zh) | 2019-08-23 |
| IL302336B1 (en) | 2025-07-01 |
| JP2019533019A (ja) | 2019-11-14 |
| ES2924257T3 (es) | 2022-10-05 |
| IL302336B2 (en) | 2025-11-01 |
| US11090308B2 (en) | 2021-08-17 |
| EP4112056B1 (en) | 2026-01-21 |
| US20240156826A1 (en) | 2024-05-16 |
| KR20190109387A (ko) | 2019-09-25 |
| WO2018075650A1 (en) | 2018-04-26 |
| IL266054B1 (en) | 2023-06-01 |
| US20200230146A1 (en) | 2020-07-23 |
| US11806353B2 (en) | 2023-11-07 |
| EP3528817B1 (en) | 2022-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3528817T3 (da) | Fremgangsmåder til behandling af leverforstyrrelser eller lipidforstyrrelser med en thr-beta-agonist | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| EP3341512A4 (en) | CHIRAL STRUCTURES WITH ADJUSTABLE AUXETIC EFFECTS | |
| DK3365684T3 (da) | Fremgangsmåde til berigelse af cellefrie nukleosomer | |
| DK3473621T3 (da) | Fremgangsmåde til fremstilling af diphenylmethan-derivat | |
| DK3201361T3 (da) | Fremgangsmåder til kvantificering af cellefrit DNA | |
| DK3433266T3 (da) | Fremgangsmåder til behandling af mitokondrieforstyrrelser | |
| DK3155101T3 (da) | Sammensætninger og fremgangsmåder til ekspression af CRISPR-leder-RNA´er under anvendelse af H1-promotoren | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3368683T3 (da) | Fremgangsmåde til kvantifikationen af pd-l1 | |
| DK3417179T3 (da) | Forbindelsesmiddel samt fremgangsmåde til forbindelse af to komponenter | |
| DK3288577T3 (da) | Adiponectin-peptidomimetika til behandling af øjenlidelser | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3134084T3 (da) | Fremgangsmåde til behandling af lungeadenokarcinom | |
| DK3579826T3 (da) | Fremgangsmåder til behandling af cdkl5-lidelser med forbindelsen ov329 | |
| DK3487443T3 (da) | Fremgangsmåde til opmåling af en implantat-implantat-situation | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DK3191498T3 (da) | Fremgangsmåde til fremstilling af 2'-o-fucosyllactose | |
| DK3114235T3 (da) | Fremgangsmåde til bestemmelse af risiko for 5-fluorouracil-toksicitet | |
| DK3515455T3 (da) | Forbindelser til behandling af lidelser i lipoproteinmetabolismen | |
| DK3177931T3 (da) | Fremgangsmåde til bestemmelse af stoffers evne til at binde til analytaktive steder | |
| DK3529236T3 (da) | Krystalformer af eravacyclin | |
| DK3240798T3 (da) | Ny fremgangsmåde til effektiv rensning af humant serum-albumin | |
| DK3523270T3 (da) | Fremgangsmåde til fremstilling af cyclopropyl-substituerede acetophenoner |